# A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer

Source: https://onco.cc/trials/nct07071714/  
OnCo record `nct07071714` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SHR-8068, Adebrelimab, Bevacizumab in colorectal cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active and no longer recruiting.

## Summary

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer is a phase 2 interventional study registered as NCT07071714 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 103 participants enrolled, started 2025-07-22 and due to reach its primary completion in 2031-10. Interventions recorded: SHR-8068 Injection, Adebrelimab Injection, Bevacizumab Injection. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07071714
- Phase: 2
- Setting: An Open, Multicenter Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 103

## Sources

- ClinicalTrials.gov NCT07071714: https://clinicaltrials.gov/study/NCT07071714

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [SHR-8068](https://onco.cc/drugs/shr-8068/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07071714.json